Iambic closed a $100 million financing to advance clinical programs discovered using its AI drug‑design platform. The financing follows data presented for a breast‑cancer candidate at ESMO and is intended to underwrite Phase I development and expanded preclinical work. The round adds to a recent pickup in venture activity for AI‑driven drug discovery companies and signals investor willingness to fund platform founders moving assets into first‑in‑human studies. Clinical readouts will test whether AI‑generated molecules translate into competitive safety and efficacy profiles.